In the latest quarter, 7 analysts provided ratings for IDEAYA Biosciences IDYA, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 6 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 3 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $40.86, a high estimate of $44.00, and a low estimate of $36.00. Surpassing the previous average price target of $37.75, the current average has increased by 8.24%.
Decoding Analyst Ratings: A Detailed Look
An in-depth analysis of recent analyst actions unveils how financial experts perceive IDEAYA Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Gregory Renza | RBC Capital | Raises | Outperform | $43.00 | $36.00 |
| Gregory Renza | RBC Capital | Maintains | Outperform | $36.00 | - |
| Anupam Rama | JP Morgan | Raises | Overweight | $41.00 | $35.00 |
| Robert Driscoll | Wedbush | Maintains | Outperform | $43.00 | - |
| Vanck Zhu | Guggenheim | Lowers | Buy | $44.00 | $48.00 |
| Robert Driscoll | Wedbush | Maintains | Outperform | $43.00 | - |
| Gregory Renza | RBC Capital | Raises | Outperform | $36.00 | $32.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to IDEAYA Biosciences. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of IDEAYA Biosciences compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for IDEAYA Biosciences's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
To gain a panoramic view of IDEAYA Biosciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on IDEAYA Biosciences analyst ratings.
About IDEAYA Biosciences
IDEAYA Biosciences Inc an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
Key Indicators: IDEAYA Biosciences's Financial Health
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Negative Revenue Trend: Examining IDEAYA Biosciences's financials over 3 months reveals challenges. As of 30 September, 2023, the company experienced a decline of approximately -72.94% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -341.38%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -5.44%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): IDEAYA Biosciences's ROA excels beyond industry benchmarks, reaching -5.17%. This signifies efficient management of assets and strong financial health.
Debt Management: IDEAYA Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
Analyst Ratings: Simplified
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
